AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2531117
Drug: Single-dose spectinomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose spectinomycin (TRO)
Trial: 21699484
Drug: Bardoxolone methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bardoxolone methyl 25 mg once daily
Trial: 21699484
Drug: Bardoxolone methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bardoxolone methyl 75 mg once daily
Trial: 21699484
Drug: Bardoxolone methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bardoxolone methyl 150 mg once daily
Trial: 15380912
Drug: Nutritional intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intervention (3 x 125 ml, 2.38 MJ/day)
Trial: 11808987
Drug: Spa therapy
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa therapy for 3 weeks
Trial: 9756115
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron therapy (total dose 1050 mg over seven consecutive dialysis sessions and supplemental monthly doses)
Trial: 25559730
Drug: Probiotic administration
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic administration (twice daily, initiated within 10 days of burn until wound closure)
Trial: 25559730
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration (twice daily, initiated within 10 days of burn until wound closure)
Trial: 21768631
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment in a cast
Trial: 16274054
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with Photosense, 0.05 mg/kg, performed on day 3 after administration, using a laser at 675 nm and a light dose of 120 J/cm2
Trial: 12420854
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (2 g/200 mg)
Trial: 9452274
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA), 500 mg, twice daily for 12 weeks
Trial: 791564
Drug: Methyldopa administered
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa administered once at bedtime (HS)
Trial: 791564
Drug: Methyldopa administered
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa administered three times daily (TID)
Trial: 25300706
Drug: Warfarin (INR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (INR 2.0‐3.5)
Trial: 18077494
Drug: 5 min
RxNorm normalized name: Creon 5 Minimicrospheres Delayed-Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 min treatment
Trial: 18077494
Drug: 2 min
RxNorm normalized name: Accu-Clear 2 Minute Pregnancy Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 min treatment
Trial: 10919681
Drug: CFC pressurized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFC pressurized metered dose inhaler (pMDI; Ventolin)
Trial: 8816621
Drug: Luteal support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal support with oral E2 (2 mg three times daily) and vaginal P (100 mg twice daily) starting on the day of retrieval and ET
Trial: 4050728
Drug: Iron treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron treatment (30 mg iron as ferrous sulfate given before a meal)
Trial: 25840585
Drug: Probiotic lozenge
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lozenge containing two strains of Lactobacillus reuteri, taken once daily for 17 months.
Trial: 25840585
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge without active bacteria, taken once daily for 17 months.
Trial: 22219013
Drug: FOLFIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI plus cetuximab (400 mg/m2 day 1, followed by 250 mg/m2 weekly)
Trial: 22219013
Drug: FOLFIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI plus bevacizumab (5 mg/kg every 2 weeks)
Trial: 2058557
Drug: Sotalol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (1.5 mg/kg over 10 minutes)
Trial: 6352951
Drug: Weekly blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly blood pressure checks
Trial: 30678553
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Pembrolizumab plus chemotherapy)
Trial: 19228151
Drug: Withdrawal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal therapy followed by neurologist (group A)
Trial: 19228151
Drug: Withdrawal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal therapy followed by primary care physician (group B)
Trial: 16297576
Drug: Soy-rich diet
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy-rich diet (25 g soy protein, >50 mg/day isoflavones)
Trial: 15330019
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) combined with intermittent pneumatic compression
Trial: 15330019
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) combined with graduated compression stockings
Trial: 11200857
Drug: Psychoeducational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducational intervention (eight sessions) followed by outpatient treatment
Trial: 11200857
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who dropped out of outpatient treatment
Trial: 9294113
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 to 20 mg/d)
Trial: 8112205
Drug: DHEP plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEP plaster (180 mg, applied b.i.d. for 14 days)
Trial: 3106210
Drug: High fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat load (3 g/kg/day)
Trial: 3106210
Drug: Medium fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium fat dosage (1.5 g/kg/day)
Trial: 19595361
Drug: Net decrease
RxNorm normalized name: [(im-Bzl)-D-His6,Pro9-NEt]-gonadotropin releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Net decrease in T-wave amplitude during reperfusion therapy
Trial: 9598491
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral sertraline
Trial: 9598491
Drug: Chronic open
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic open label treatment with sertraline
Trial: 7873461
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus pamidronate (Aredia) 45 mg intravenously every 3 weeks
Trial: 7873461
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus pamidronate (Aredia)
Trial: 3285485
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 120 mg/d plus diethylstilbestrol (DES) 0.1 to 3 mg/d
Trial: 3285485
Drug: Diethylstilbestrol (DES)
RxNorm normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (DES) 0.1 to 3 mg/d
Trial: 11557459
Drug: IDV-RTV 800-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDV-RTV 800-100 mg
Trial: 11557459
Drug: IDV-RTV 800-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDV-RTV 800-200 mg
Trial: 11557459
Drug: IDV-RTV 400-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDV-RTV 400-400 mg
Trial: 11557459
Drug: Placebo of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of IDV with RTV 100 mg
Trial: 11557459
Drug: Placebo of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of IDV with RTV 200 mg
Trial: 11557459
Drug: Placebo of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of IDV with RTV 400 mg
Trial: 31257177
Drug: Trastuzumab duocarmazine
RxNorm normalized name: Trastuzumab duocarmazine
DrugBank: Trastuzumab duocarmazine (DB16342)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab duocarmazine (1.2 mg/kg recommended phase 2 dose)
Trial: 29328779
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment settings
Trial: 24904204
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy (control group).
Trial: 9935020
Drug: Captopril 6.25
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 6.25 mg increasing to 50 mg t.d.s. after intravenous streptokinase
Trial: 7561799
Drug: Oral brivudin
RxNorm normalized name: Brivudine
DrugBank: Brivudine (DB03312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral brivudin (125 mg tablet every 6 hours for 5 days)
Trial: 7561799
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (10 mg/kg infused over 1 hour every 8 hours for 5 days)
Trial: 7561799
Drug: Oral brivudin
RxNorm normalized name: Brivudine
DrugBank: Brivudine (DB03312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral brivudin
Trial: 2222030
Drug: Percutaneous needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous needle aspiration with drugs (metronidazole, diloxanide, chloroquine)
Trial: 2222030
Drug: Drugs alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs alone (metronidazole, diloxanide, chloroquine)
Trial: 2222030
Drug: Drugs alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs alone (non-aspirated group)
Trial: 31285082
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2, carboplatin AUC 6 mg/mL/min, and bevacizumab 15 mg/kg every 21 days until disease progression, complete remission, or limiting toxicity.
Trial: 31285082
Drug: Paclitaxel, carboplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel, carboplatin, and bevacizumab treatment
Trial: 29195602
Drug: Erythrocytapheresis (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythrocytapheresis (treatment group)
Trial: 29195602
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment by plasmapheresis (control group)
Trial: 25644578
Drug: 0.20 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20 ml local anaesthetic per mm² cross-sectional nerve area (starting volume)
Trial: 25644578
Drug: 0.02 ml.mm(‐2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 ml.mm(‐2) reduction in local anaesthetic volume if surgical anaesthesia was adequate
Trial: 21647577
Drug: Dextroamphetamine (AMP)
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (AMP) 10 mg and 20 mg
Trial: 21647577
Drug: Δ(9)-tetrahydrocannabinol (THC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ(9)-tetrahydrocannabinol (THC) 7.5 mg and 15 mg
Trial: 27687347
Drug: Sugammadex (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (4 mg/kg)
Trial: 17449580
Drug: 3.2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 g/d CLA
Trial: 17449580
Drug: 6.4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4 g/d CLA
Trial: 17449580
Drug: Placebo (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8 g safflower oil/d)
Trial: 8186134
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% cream applied twice daily for 1 week
Trial: 8186134
Drug: Clotrimazole 1%
RxNorm normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole 1% cream applied twice daily for 4 weeks
Trial: 29068831
Drug: Balanced colloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced colloid solution
Trial: 26630142
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care plus immunosuppressive therapy (immunosuppression group) for 3 years
Trial: 11119091
Drug: Bladder infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder infusion before trial of voiding (ToV)
Trial: 8814495
Drug: Erythropoietin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin therapy (45‐60 U/kg, three times a week)
Trial: 8814495
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (haemodialysis patients without erythropoietin treatment)
Trial: 1415040
Drug: Whole-cell pertussis-component
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell pertussis-component diphtheria-tetanus-pertussis vaccine (DTP)
Trial: 1415040
Drug: Acellular pertussis-component
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis-component diphtheria-tetanus-pertussis vaccine (APDT)
Trial: 29661413
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (1 μg kg-1)
Trial: 29661413
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine via atomiser (1 μg kg-1)
Trial: 29661413
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine by drops (1 μg kg-1)
Trial: 29661413
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (both atomisation and drops)
Trial: 24691606
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of tadalafil daily for 24 weeks
Trial: 14711459
Drug: Chicken extract
RxNorm normalized name: chicken extract 50 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicken extract (CE) group, 70 mL/bottle, three times a day, providing 18 g protein from the 37th week of pregnancy to 3 days postpartum.
Trial: 14711459
Drug: Control group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group, high protein supplement was restricted.
Trial: 10423058
Drug: Successful therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful therapy (omeprazole or fundoplication)
Trial: 2160441
Drug: VLCD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VLCD with dietary fibre (30 g/day)
Trial: 7031568
Drug: Heparin prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin prophylaxis (5,000 micro sodium heparin subcutaneously every 12 hours)
Trial: 22234648
Drug: Twice-a-week supervised
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-week supervised aerobic and resistance training plus exercise counselling (exercise group)
Trial: 20138446
Drug: Iron intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron intake of 1.11 mg/kg/day (SD 0.06)
Trial: 7942250
Drug: Tonic water
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonic water administration (placebo)
Trial: 24498968
Drug: Enzyme-treated asparagus
RxNorm normalized name: Asparagus
DrugBank: Asparagus (DB10503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-treated asparagus extract (ETAS) at 200 mg/kg body weight
Trial: 24498968
Drug: Enzyme-treated asparagus
RxNorm normalized name: Asparagus
DrugBank: Asparagus (DB10503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-treated asparagus extract (ETAS) at 1000 mg/kg body weight
Trial: 24498968
Drug: Enzyme-treated asparagus
RxNorm normalized name: Asparagus
DrugBank: Asparagus (DB10503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-treated asparagus extract (ETAS) at 150 mg/d for 7 days
Trial: 24498968
Drug: Enzyme-treated asparagus
RxNorm normalized name: Asparagus
DrugBank: Asparagus (DB10503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-treated asparagus extract (ETAS) at 0.125 mg/mL
Trial: 24498968
Drug: Enzyme-treated asparagus
RxNorm normalized name: Asparagus
DrugBank: Asparagus (DB10503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-treated asparagus extract (ETAS) at 1.0 mg/mL
Trial: 18090049
Drug: nevirapine 400
RxNorm normalized name: nevirapine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nevirapine 400 mg once-daily (n = 31)
Trial: 18090049
Drug: nevirapine 200
RxNorm normalized name: nevirapine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nevirapine 200 mg twice-a-day (n = 31)
Trial: 9923580
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice with 2 mg pranidipine
Trial: 9923580
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice with 2 mg pranidipine
Trial: 9923580
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with 2 mg pranidipine
Trial: 8087824
Drug: Captopril (50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50-200 mg daily)
Trial: 8087824
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN; 5 and 15 mg)
Trial: 8087824
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with captopril and ISDN
Trial: 1103563
Drug: Diphenidol (1,1‐diphenyl‐4‐piperidino‐l‐butanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenidol (1,1‐diphenyl‐4‐piperidino‐l‐butanol hydrochloride)
Trial: 19519891
Drug: All LTFU
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All LTFU participants in the treatment group had the event; none in the control group (worst case scenario)
Trial: 17900783
Drug: Chitosan mouth
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan mouth rinse solution
Trial: 10204813
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg controlled‐release nifedipine once daily
Trial: 10204813
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sustained‐release nifedipine twice daily
Trial: 27974169
Drug: Antibiotics-first treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics-first treatment (intravenous ertapenem for ≥48 hours, followed by oral cefdinir and metronidazole)
Trial: 27974169
Drug: Antibiotics-first treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics-first treatment
Trial: 24039797
Drug: Complementary food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary food supplements containing multiple vitamins and minerals provided daily for 1.5 years.
Trial: 21435103
Drug: Fat infusion
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat infusion (F)
Trial: 21435103
Drug: Carbohydrate infusion
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate infusion (C)
Trial: 21435103
Drug: Protein infusion
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein infusion (P)
Trial: 14762367
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 patients with normal platelet counts and no previous extended exposure to heparin)
Trial: 9517521
Drug: Cisapride 5
RxNorm normalized name: cisapride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 5 mg three times daily for 12 weeks
Trial: 1333617
Drug: Clonidine (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (dose not specified)
Trial: 23232168
Drug: Epley maneuver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epley maneuver (rehabilitation treatment)
Trial: 19139884
Drug: Ipilimumab (anti-CTLA-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (anti-CTLA-4 monoclonal antibody)
Trial: 9849693
Drug: G‐CSF starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF starting on day +1
Trial: 9849693
Drug: G‐CSF starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF starting on day +7